Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow

Coherus Oncology will release 2025 financial results on March 9, 2026, followed by a conference call and webcast.

Quiver AI Summary

Coherus Oncology, Inc. announced it will release its full year and fourth quarter 2025 financial results on March 9, 2026, after market close. Following the release, Coherus' management will hold a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Interested parties can access the call by pre-registering online and will be able to view a webcast replay afterward. Coherus Oncology is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI®, and is developing additional pipeline candidates targeting various cancers. The company's strategy includes expanding LOQTORZI sales and advancing new clinical indications to improve patient outcomes.

Potential Positives

Coherus Oncology is preparing to release its full year and fourth quarter 2025 financial results, indicating transparency and accountability to shareholders.
The company will host a conference call and webcast for stakeholders to discuss financial results and provide a general business update, promoting engagement with investors.
Coherus has an approved PD-1 inhibitor, LOQTORZI®, and a diverse pipeline of mid-stage clinical candidates targeting various cancers, highlighting its ongoing commitment to oncology innovation.
The Company’s strategy focuses on growing sales of LOQTORZI and advancing new indications, showcasing its proactive approach in maximizing product value and expanding treatment options for patients.

Potential Negatives

The press release does not provide any actual financial results or updates, which may lead to skepticism about the company's performance and transparency.
Coherus has not provided specific details about expectations for financial performance, which could raise concerns among investors regarding future growth and stability.
The reliance on a pre-registration process to access the conference call may limit participation and transparency, potentially alienating certain stakeholders.

FAQ

When are Coherus Oncology's Q4 2025 financial results being released?

Coherus Oncology will release its full year and fourth quarter 2025 financial results on March 9, 2026, after market close.

How can I access the Coherus Oncology conference call?

To access the conference call, pre-register at the provided link to receive dial-in information and a personal PIN.

What time does the Coherus conference call start?

The conference call will begin at 4:30 p.m. Eastern Time on March 9, 2026.

Where can I find the webcast of the financial results discussion?

A live and archived webcast will be available on the Coherus website under the “Investors” section.

What innovative treatments does Coherus Oncology offer?

Coherus offers LOQTORZI®, a PD-1 inhibitor, and has a pipeline of antibody immunotherapy candidates for various cancers.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$CHRS Revenue

$CHRS had revenues of $11.6M in Q3 2025. This is an increase of 91.19% from the same period in the prior year.

You can track CHRS financials on Quiver Quantitative's CHRS stock page.

$CHRS Hedge Fund Activity

We have seen 59 institutional investors add shares of $CHRS stock to their portfolio, and 60 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TANG CAPITAL MANAGEMENT LLC removed 2,372,853 shares (-46.6%) from their portfolio in Q4 2025, for an estimated $3,369,451
MACQUARIE GROUP LTD removed 899,999 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,277,998
RUBRIC CAPITAL MANAGEMENT LP removed 867,800 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,423,192
TEJARA CAPITAL LTD removed 698,770 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,145,982
MILLENNIUM MANAGEMENT LLC added 660,451 shares (+inf%) to their portfolio in Q4 2025, for an estimated $937,840
GSA CAPITAL PARTNERS LLP added 477,481 shares (+inf%) to their portfolio in Q4 2025, for an estimated $678,023
TWO SIGMA INVESTMENTS, LP added 468,163 shares (+1310.9%) to their portfolio in Q4 2025, for an estimated $664,791

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CHRS Price Targets

Multiple analysts have issued price targets for $CHRS recently. We have seen 2 analysts offer price targets for $CHRS in the last 6 months, with a median target of $7.0.

Here are some recent targets:

Jay Olson from Oppenheimer set a target price of $10.0 on 01/22/2026
Jason McCarthy from Maxim Group set a target price of $4.0 on 09/04/2025

Full Release

REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI343f960d41224739b123cc4c86fdce7a

Webcast: https://edge.media-server.com/mmc/p/2otjwz7w

The press release with the full year and fourth quarter 2025 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations .

Please dial in 15 minutes early to ensure a timely connection to the call.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI ^® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

Coherus Oncology Contact Information:

For Investors:

Carrie Graham
Vice President, Investor Relations & Advocacy
[email protected]